The effects of grape seed extract supplementation on cardiovascular risk factors, liver enzymes and hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study

Study answer

What this study found

Grape seed extract showed an overall favorable effect versus placebo after 2 months, improving lipid profile, blood pressure, liver enzymes, and ultrasound-determined hepatic steatosis. Post-intervention LDL-c was 101.89 ± 22.88 mg/dl with GSE versus 125.82 ± 30.15 mg/dl with placebo (P = 0.003), total cholesterol was 182.58 ± 21.59 versus 204.18 ± 33.67 mg/dl (P = 0.01), HDL-c was 48.91 ± 7.32 versus 42.93 ± 7.33 mg/dl (P = 0.006), LDL/HDL ratio was 2.13 ± 0.58 versus 3.02 ± 0.87 (P < 0.001), and AIP was 0.50 ± 0.14 versus 0.61 ± 0.12 (P = 0.008). SBP, DBP, and MAP were also lower with GSE…

Study & population

Randomized, double-blind, placebo-controlled parallel study in overweight or obese adults with ultrasound-confirmed moderate to severe non-alcoholic fatty liver disease (NAFLD).

Intervention

Oral grape seed extract (GSE) 520 mg/day was given as two 260 mg tablets taken with the morning and evening snacks for 2 months.

Key limitation

The trial was small, single-center, and short in duration, with only 25 participants in the active arm and 2 months of follow-up.

View full study detailsView sourceOpen PDF

Original abstract